# Study to Evaluate the Safety and PK of LODIENT Tablet 80/2.5mg in Healthy Adult Volunteers

> **NCT04667624** · PHASE1 · COMPLETED · sponsor: **Hanlim Pharm. Co., Ltd.** · enrollment: 32 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** Twynsta
- **DRUG:** LodineT

## Key facts

- **NCT ID:** NCT04667624
- **Lead sponsor:** Hanlim Pharm. Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-02-29
- **Primary completion:** 2020-04-28
- **Final completion:** 2020-05-18
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2020-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04667624

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04667624, "Study to Evaluate the Safety and PK of LODIENT Tablet 80/2.5mg in Healthy Adult Volunteers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04667624. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*